Delivery of therapeutic siRNA to the lung endothelium via novel Lipoplex formulation DACC.
about
siRNA delivery to the lung: what's new?Development of small RNA delivery systems for lung cancer therapy.Effect of surface properties on liposomal siRNA delivery.RNAi targeting multiple cell adhesion molecules reduces immune cell recruitment and vascular inflammation after myocardial infarction.Lipid nanoparticles for gene delivery.Nanoparticle-mediated delivery of siRNA for effective lung cancer therapy.Pharmacokinetics and biodistribution of recently-developed siRNA nanomedicinesA tumor-targeting cRGD-EGFR siRNA conjugate and its anti-tumor effect on glioblastoma in vitro and in vivo.Delivery strategies and potential targets for siRNA in major cancer typesCancer nanomedicine: progress, challenges and opportunities.RNAi therapy to the wall of arteries and veins: anatomical, physiologic, and pharmacological considerations.Therapeutic siRNA targeting endothelial KDR decreases portosystemic collateralization in portal hypertension.No significant impact of Foxf1 siRNA treatment in acute and chronic CCl4 liver injury.Antiphospholipid antibodies induce thrombosis by PP2A activation via apoER2-Dab2-SHC1 complex formation in endothelium.Liver-specific Fas silencing prevents galactosamine/lipopolysaccharide-induced liver injury.
P2860
Q27022043-1D00641D-7567-4DF4-93C9-FD330712E6E7Q35380932-C021EF4F-FD12-48E5-882E-DABC7F263F26Q36421379-99E9A130-6B93-4A6C-B609-38FAD1E84267Q37445494-EA23EC71-A959-4635-9F96-10DD5660E801Q38269555-925B8F3C-36A4-40EE-972A-3A9F529CA2EFQ38451918-9B8C8ABD-DBB6-448E-9B15-66D2FCC5FDBAQ38674444-9ED77DC8-0924-44FD-9D8F-DC680621AB08Q38717131-BF6CF3FA-1F6A-4C4A-A700-37DDC6C17D4DQ38853191-C686C078-4AB9-40C1-B023-49000F398930Q39005226-D25F4C0D-7179-4728-B64B-44476E54DC6FQ42048496-4E76AB45-8CF8-4472-B9F0-B4A1D91B2A87Q47111424-A75A93AA-8147-4CF1-9BA7-C2A42191BCDFQ50228094-EA4EA013-61DD-41DC-BB28-FA43B1F824AAQ52368982-0BDB62A7-F4DF-4C03-B27C-9AB0670CFE97Q53640671-09A2F3AC-CB34-4DFE-98C3-A5BC1DAD74C3
P2860
Delivery of therapeutic siRNA to the lung endothelium via novel Lipoplex formulation DACC.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh
2014年學術文章
@zh-hant
name
Delivery of therapeutic siRNA ...... vel Lipoplex formulation DACC.
@en
type
label
Delivery of therapeutic siRNA ...... vel Lipoplex formulation DACC.
@en
prefLabel
Delivery of therapeutic siRNA ...... vel Lipoplex formulation DACC.
@en
P2093
P2860
P356
P1433
P1476
Delivery of therapeutic siRNA ...... vel Lipoplex formulation DACC.
@en
P2093
Jörg Kaufmann
M Eisermann
U Schaeper
P2860
P304
P356
10.1038/MT.2013.291
P577
2014-01-06T00:00:00Z